Title:
APPARATUS, SYSTEM, AND METHOD FOR CREATING BIOLOGICALLY PROTECTED/ENHANCED SPACES IN VIVO
Document Type and Number:
WIPO Patent Application WO/2012/122107
Kind Code:
A3
Abstract:
The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.
Inventors:
KNEZEVICH CHARLES (US)
SILVETZ ROBERT D (US)
SILVETZ ROBERT D (US)
Application Number:
PCT/US2012/027740
Publication Date:
November 22, 2012
Filing Date:
March 05, 2012
Export Citation:
Assignee:
KNEZEVICH CHARLES (US)
SILVETZ ROBERT D (US)
SILVETZ ROBERT D (US)
International Classes:
A61K38/30; A61K35/39; A61K35/74; A61K38/17; A61K38/18; A61P3/00; A61P3/10
Foreign References:
| US20100272772A1 | 2010-10-28 | |||
| EP1454641A2 | 2004-09-08 | |||
| US20080103606A1 | 2008-05-01 |
Other References:
KIM, J. Y. ET AL.: "Effects of BCG, lymphotoxin and bee venom on insulitis and development of IDDM in non-obese diabetic mice", J. KOREAN MED. SCI., vol. 14, no. 6, December 1999 (1999-12-01), pages 648 - 652
Attorney, Agent or Firm:
PARKER, James, S. et al. (Lloyd & EisenschenkP.O. Box 14295, Gainesville FL, US)
Download PDF:
Previous Patent: COMPOSITIONS AND METHODS APC, CREB, AND BAD PATHWAYS TO ASSESS AND AFFECT CANCER
Next Patent: ROLLER CLUTCH
Next Patent: ROLLER CLUTCH